Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D7XM
|
||||
| Former ID |
DIB002150
|
||||
| Drug Name |
NC-4016
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Company |
Nanocarrier
|
||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Inhibitor | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01999491) A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma. U.S. National Institutes of Health. | ||||
| REF 2 | Effects of Treatment with Platinum Azidothymidine and Azidothymidine on Telomerase Activity and Bcl-2 Concentration in Hepatocellular Carcinoma- Induced Rats. Avicenna J Med Biotechnol. 2014 Oct-Dec;6(4): 200-209. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.